Literature DB >> 16009660

Training raters to assess adult ADHD: reliability of ratings.

Lenard A Adler1, Thomas Spencer, Stephen V Faraone, Fred W Reimherr, Douglas Kelsey, David Michelson, Joseph Biederman.   

Abstract

The standardization of ADHD ratings in adults is important given their differing symptom presentation. The authors investigated the agreement and reliability of rater standardization in a large-scale trial of atomoxetine in adults with ADHD. Training of 91 raters for the investigator-administered ADHD Rating Scale (ADHDRS-IV-Inv) occurred prior to initiation of a large, 31-site atomoxetine trial. Agreement between raters on total scores was established in two ways: (a) by Kappa coefficient (rater agreement for each item with the percentage of raters that had identical item-by-item scores) and (b) intraclass correlation coefficients (reliability). For the ADHDRS-IV-Inv, rater agreement was moderate, and reliability, as measured by Cronbach's alpha, was substantial. The data indicate that clinicians can be trained to reliably evaluate ADHD in adults using the ADHDRS-IV-Inv.

Entities:  

Mesh:

Year:  2005        PMID: 16009660     DOI: 10.1177/1087054705277168

Source DB:  PubMed          Journal:  J Atten Disord        ISSN: 1087-0547            Impact factor:   3.256


  12 in total

1.  Bupropion for the treatment of methamphetamine dependence in non-daily users: a randomized, double-blind, placebo-controlled trial.

Authors:  Ann L Anderson; Shou-Hua Li; Denka Markova; Tyson H Holmes; Nora Chiang; Roberta Kahn; Jan Campbell; Daniel L Dickerson; Gantt P Galloway; William Haning; John D Roache; Christopher Stock; Ahmed M Elkashef
Journal:  Drug Alcohol Depend       Date:  2015-02-07       Impact factor: 4.492

2.  Efficacy and safety of the novel α₄β₂ neuronal nicotinic receptor partial agonist ABT-089 in adults with attention-deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled crossover study.

Authors:  George Apostol; Walid Abi-Saab; Christopher J Kratochvil; Lenard A Adler; Weining Z Robieson; Laura M Gault; Yili L Pritchett; David Feifel; Michelle A Collins; Mario D Saltarelli
Journal:  Psychopharmacology (Berl)       Date:  2011-07-12       Impact factor: 4.530

3.  Divergence by ADHD subtype in smoking cessation response to OROS-methylphenidate.

Authors:  Lirio S Covey; Mei-Chen Hu; Judith Weissman; Ivana Croghan; Lenard Adler; Theresa Winhusen
Journal:  Nicotine Tob Res       Date:  2011-06-07       Impact factor: 4.244

4.  An exploration of site effects in a multisite trial of OROS-methylphenidate for smokers with attention deficit/hyperactivity disorder.

Authors:  Lirio S Covey; Mei-Chen Hu; Carla A Green; Gregory Brigham; Richard D Hurt; Lenard Adler; Theresa Winhusen
Journal:  Am J Drug Alcohol Abuse       Date:  2011-09       Impact factor: 3.829

5.  Modafinil for the treatment of methamphetamine dependence.

Authors:  Ann L Anderson; Shou-Hua Li; Kousick Biswas; Frances McSherry; Tyson Holmes; Erin Iturriaga; Roberta Kahn; Nora Chiang; Thomas Beresford; Jan Campbell; William Haning; Joseph Mawhinney; Michael McCann; Richard Rawson; Christopher Stock; Dennis Weis; Elmer Yu; Ahmed M Elkashef
Journal:  Drug Alcohol Depend       Date:  2011-08-12       Impact factor: 4.492

6.  Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder.

Authors:  Richard H Weisler; Gahan J Pandina; Ella J Daly; Kimberly Cooper; Cristiana Gassmann-Mayer
Journal:  CNS Drugs       Date:  2012-05-01       Impact factor: 5.749

7.  Who cares for patients with attention-deficit/hyperactivity disorder (ADHD)? Insights from Nordbaden (Germany) on administrative prevalence and physician involvement in health care provision.

Authors:  Michael Schlander; Oliver Schwarz; Goetz-Erik Trott; Michael Viapiano; Norbert Bonauer
Journal:  Eur Child Adolesc Psychiatry       Date:  2007-10       Impact factor: 4.785

8.  Impact of attention-deficit/hyperactivity disorder (ADHD) treatment on smoking cessation intervention in ADHD smokers: a randomized, double-blind, placebo-controlled trial.

Authors:  Theresa M Winhusen; Eugene C Somoza; Gregory S Brigham; David S Liu; Carla A Green; Lirio S Covey; Ivana T Croghan; Lenard A Adler; Roger D Weiss; Jeffrey D Leimberger; Daniel F Lewis; Emily M Dorer
Journal:  J Clin Psychiatry       Date:  2010-05-18       Impact factor: 4.384

9.  Baseline characteristics of European and non-European adult patients with attention deficit hyperactivity disorder participating in a placebo-controlled, randomized treatment study with atomoxetine.

Authors:  Himanshu Upadhyaya; Lenard A Adler; Miguel Casas; Alexandra Kutzelnigg; David Williams; Yoko Tanaka; Jody Arsenault; Rodrigo Escobar; Albert J Allen
Journal:  Child Adolesc Psychiatry Ment Health       Date:  2013-05-06       Impact factor: 3.033

10.  Dopamine transporter 3'UTR VNTR genotype is a marker of performance on executive function tasks in children with ADHD.

Authors:  Sherif Karama; Natalie Grizenko; Edmund Sonuga-Barke; Alysa Doyle; Joseph Biederman; Valentin Mbekou; Anna Polotskaia; Marina Ter-Stepanian; Rosherrie De Guzman; Johanne Bellingham; Sarojini Sengupta; Ridha Joober
Journal:  BMC Psychiatry       Date:  2008-06-17       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.